Bode John B's Form 4 filing
Zevra Therapeutics, Inc. (ZVRA) · filed May 19, 2023
- Accession no.
- 0001437749-23-015335
- Filed
- May 19, 2023
- Trade date
- May 18, 2023
- Filing delay
- 1 day
- Rule 10b5-1 plan
- Not checked
This filing lists 6 non-derivative transactions and 0 derivative transactions. Open-market purchases total $50.4K. It was filed 1 day after the trade.
Reporting owners
A Form 4 can have several reporting owners, such as a person and a fund they control. Trade tables show the first one.
| Owner | Relationship to the company |
|---|---|
| Bode John BCIK 0001612084 | Director |
Non-derivative securities (Table I)
Acquisitions and disposals of common stock and similar shares, one row per line on the filing.
| Trade date | Security | Transaction | Shares | Price | Value | Shares after | Ownership | Flags |
|---|---|---|---|---|---|---|---|---|
| May 18, 2023 | Common Stock | PPurchaseAcquired | +1,390 | $5.04 | +$7,005.6 | 1,390 | Direct | |
| May 18, 2023 | Common Stock | PPurchaseAcquired | +300 | $5.04 | +$1,512 | 1,690 | Direct | |
| May 18, 2023 | Common Stock | PPurchaseAcquired | +1,000 | $5.04 | +$5,040 | 2,690 | Direct | |
| May 18, 2023 | Common Stock | PPurchaseAcquired | +4,759 | $5.04 | +$23,985.36 | 7,449 | Direct | |
| May 18, 2023 | Common Stock | PPurchaseAcquired | +100 | $5.05 | +$505 | 7,549 | Direct | |
| May 18, 2023 | Common Stock | PPurchaseAcquired | +2,451 | $5.05 | +$12,377.55 | 10,000 | Direct |
Footnotes
Livermore does not store Form 4 footnotes. For price ranges, how indirect holdings are held and trading plan details, read the original on SEC EDGAR.